Molecular features, such as isocitrate dehydrogenase (IDH) mutations, TERT promoter mutations, MGMT promoter methylation, and chromosome 1p/19q co-deletion status, have been found to serve as indicators for glioma prognosis and classifications (4, 5). This evidence concerns the gene MGMT and central nervous system cancer.